^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    ATP150

    i
    Other names: ATP150, ATP 150, ATP-150
    Associations

    News

    Trials
    Company:
    Boehringer Ingelheim
    Drug class:
    Immunostimulant
    Related drugs:
    Associations

    News

    Trials
    24d
    A Study to Test KISIMA-02 Vaccine-based Immunotherapy and Ezabenlimab in People With Pancreatic Cancer (clinicaltrials.gov)
    P1, N=58, Active, not recruiting, Boehringer Ingelheim | Trial completion date: Mar 2027 --> Aug 2027
    Trial completion date
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    ezabenlimab (BI 754091) • ATP150 • ATP152 • VSV-GP154
    1m
    A Study to Test KISIMA-02 Vaccine-based Immunotherapy and Ezabenlimab in People With Pancreatic Cancer (clinicaltrials.gov)
    P1, N=58, Active, not recruiting, Boehringer Ingelheim | Trial completion date: Jun 2027 --> Mar 2027 | Trial primary completion date: Jun 2027 --> Mar 2027
    Trial completion date • Trial primary completion date
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    ezabenlimab (BI 754091) • ATP150 • ATP152 • VSV-GP154
    5ms
    A Study to Test KISIMA-02 Vaccine-based Immunotherapy and Ezabenlimab in People With Pancreatic Cancer (clinicaltrials.gov)
    P1, N=57, Active, not recruiting, Boehringer Ingelheim | Recruiting --> Active, not recruiting | N=171 --> 57 | Trial completion date: May 2029 --> Jun 2027 | Trial primary completion date: Feb 2029 --> Jun 2027
    Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    ezabenlimab (BI 754091) • ATP150 • ATP152 • VSV-GP154
    7ms
    A Study to Test KISIMA-02 Vaccine-based Immunotherapy and Ezabenlimab in People With Pancreatic Cancer (clinicaltrials.gov)
    P1, N=171, Recruiting, Boehringer Ingelheim | N=94 --> 171 | Trial primary completion date: Jun 2028 --> Feb 2029
    Enrollment change • Trial primary completion date
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation • KRAS G12D • KRAS G12
    |
    ezabenlimab (BI 754091) • ATP150 • ATP152 • VSV-GP154
    10ms
    KISIMA-02: A Study to Evaluate ATP150/ATP152/ATP162, VSV-GP154 and Ezabenlimab in Patients With Pancreatic Ductal Adenocarcinoma (clinicaltrials.gov)
    P1, N=94, Recruiting, Amal Therapeutics | Trial completion date: Mar 2027 --> May 2029 | Trial primary completion date: Dec 2026 --> Jun 2028
    Trial completion date • Trial primary completion date
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation • KRAS G12D • KRAS G12
    |
    ezabenlimab (BI 754091) • ATP150 • ATP152 • VSV-GP154
    over2years
    A Study to Evaluate ATP150/ATP152, VSV-GP154 and Ezabenlimab in Patients With KRAS G12D/G12V Mutated PDAC (KISIMA-02) (clinicaltrials.gov)
    P1, N=85, Recruiting, Amal Therapeutics | Phase classification: P1b --> P1
    Phase classification
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation • KRAS G12D • KRAS G12V • KRAS G12
    |
    ezabenlimab (BI 754091) • ATP150 • ATP152 • VSV-GP154
    3years
    A Study to Evaluate ATP150/ATP152, VSV-GP154 and Ezabenlimab in Patients With KRAS G12D/G12V Mutated PDAC (KISIMA-02) (clinicaltrials.gov)
    P1b, N=85, Recruiting, Amal Therapeutics
    New P1 trial
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation • KRAS G12D • KRAS G12V • KRAS G12
    |
    ezabenlimab (BI 754091) • ATP150 • ATP152 • Kisima (ATP128) • VSV-GP154